The significant EPS and revenue beat combined with raised guidance is a strong positive catalyst. Monitor the Q3 earnings call for sustainability of organic growth momentum and whether the tariff refund is a one-time benefit or signals broader trade policy tailwinds. The Novum IQ LVP shipment hold remains a headwind for Infusion Systems, but broad-based segment growth suggests underlying demand is solid.
Price Chart
Executive Summary
Baxter reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted EPS of $0.56 (vs $0.37 consensus, +51.4% beat) and revenue of $2.96B (vs $2.80B consensus, +5.7% beat). The company raised its full-year 2026 guidance: reported sales growth now 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), and adjusted EPS $1.95-$2.15 (from $1.85-$2.05). The beat was partly driven by a $0.11/share IEEPA tariff refund not previously contemplated in guidance.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS $0.56 vs consensus $0.37 (+51.4% beat)
- Q2 2026 revenue $2.96B vs consensus $2.80B (+5.7% beat)
- Revenue grew 5% YoY on both reported and organic basis, with all segments and divisions growing
- Full-year 2026 guidance raised: reported sales growth 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), adjusted EPS $1.95-$2.15 (from $1.85-$2.05)
- GAAP EPS $0.26 vs $0.24 YoY (+8%); adjusted EPS $0.56 vs $0.59 YoY (-5%) due to higher-cost inventory and cost reclassification, partially offset by $0.11/share tariff refund
- Free cash flow $181M in Q2, $257M YTD
- Quarterly dividend declared at $0.01/share, payable October 1, 2026
Financial Impact
EPS beat of $0.19 (51.4%) on $0.37 consensus; revenue beat of $160M (5.7%) on $2.80B consensus; guidance raised by $0.10-$0.10 at midpoint for adjusted EPS and 2-3pp for sales growth
Risk Factors
- The $0.11/share tariff refund is non-recurring and may not repeat in H2 2026
- Novum IQ LVP shipment and installation hold continues to pressure Infusion Systems sales
- Adjusted EPS still declined 5% YoY due to higher-cost inventory and cost reclassification headwinds
- Dividend remains at $0.01/share, signaling continued balance sheet constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-050795 |
| Document: bax-20260729.htm | 0001628280-26-050795 |
| Document: 0001628280-26-050795-index-headers.html | 0001628280-26-050795 |
| Document: 0001628280-26-050795-index.html | 0001628280-26-050795 |
| Document: 0001628280-26-050795.txt | 0001628280-26-050795 |
| 8-K Data (Synthetic) | 0001628280-26-050795 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 8-K | $26.64 $23.02 | ▼ −13.59% | ▼ −11.64% | $23.49 (−11.82%) |
Aug 18, 2026 6w ago | 8-K | $26.64 $23.02 | ▼ −13.59% | ▼ −11.64% | $23.49 (−11.82%) |
Aug 12, 2026 7w ago | Institutional Cluster | $26.95 $24.18 | ▼ −10.28% | ▼ −8.38% | $23.49 (−12.84%) |
Aug 4, 2026 8w ago | 8-K | $28.35 $25.48 | ▼ −10.12% | ▼ −8.89% | $23.49 (−17.14%) |
Jul 30, 2026 9w ago | 8-K | $26.75 $25.93 | ▼ −3.07% | ▼ −7.03% | $23.49 (−12.19%) |
Jun 11, 2026 16w ago | Institutional Cluster | $20.49 $22.46 | ▼ −9.61% | ▼ −7.72% | $23.49 (−14.64%) |
May 8, 2026 21w ago | 8-K | $17.53 $20.03 | ▲ +14.26% | ▲ +14.57% | $23.49 (+34.00%) |
Apr 30, 2026 22w ago | 8-K | $17.58 $19.25 | ▲ +9.50% | ▲ +4.53% | $23.49 (+33.62%) |
Apr 29, 2026 22w ago | DEFA14A | $16.90 $19.33 | ▲ +14.38% | ▲ +8.92% | $23.49 (+38.99%) |
Mar 23, 2026 27w ago | DEFA14A | $16.61 $18.49 | ▲ +11.32% | ▲ +3.90% | $23.49 (+41.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access